Abramson, J.S., Barnes, J.A., Toomey, C.E., et al. (2008) Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and HIV-Positive Burkitt Lymphoma. ASH Annual Meeting Abstracts, 112, 3595.

has been cited by the following article:

• TITLE: Rituximab Improves Overall Survival in Patients Treated with CODOX-M/IVAC for Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and BL (BCL-U): A Single Center Experience and Review of the Literature

  AUTHORS: A. Prica, A. Pratzer, M. Cheung, K. Thompson, E. Piliotis, N. L. Berinstein, K. Imrie, R. Pradhan, A. Vyas, Z. Ghorab, D. Good, L. Zhang, R. Buckstein

  KEYWORDS: Burkitt Lymphoma, Burkitt-Like Lymphoma, CODOX-M/IVAC, MYC, Rituximab

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.1, December 26, 2014

  ABSTRACT: Background: Dose-modified (dm) CODOX-M/IVAC is commonly used for Burkitt lymphoma (BL) and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and BL (BCL-U; previously Burkitt-like lymphoma-BLL). Methods: We evaluated the clinical characteristics, outcomes and prognostic markers in patients treated with dmCODOX-M/IVAC+/- rituximab (R) at a single academic center. Results: 31 patients with BL (n = 21) or BCL-U (n = 10) were included. The median age was 45, and 90% were high risk. The 2-year overall survival (OS) and progression-free survival (PFS) were 69% and 62%, respectively, with no differences between BL and BCL-U. By multivariable analysis, rituximab use was significantly associated with improved OS (Hazard Ratio 0.15; 95% CI 0.04 - 0.56) while elevated LDH (Hazard Ratio 2.84, 95% CI 1.52 - 5.29) and rituximab use (Hazard Ratio 0.054, 95% CI 0.01 - 0.32) predicted PFS. Conclusion: DmCODOX-M/IVAC+/- R chemotherapy provides equivalent survival for both BL and BCL-U patients. The addition of rituximab improves overall and progression free survival and is recommended.